肝脏 ›› 2026, Vol. 31 ›› Issue (9): 1331-1334.

• 其他肝病 • 上一篇    下一篇

不同方案治疗晚发型妊娠期肝内胆汁淤积症的疗效及其胆汁酸组成特征

李月鑫, 仇菊, 朱沙沙, 钱进   

  1. 226500 南通 如皋市人民医院妇产科(李月鑫,仇菊,钱进),检验科(朱沙沙)
  • 收稿日期:2026-01-18 出版日期:2026-09-30 发布日期:2026-11-16
  • 通讯作者: 钱进,Email: 361741379@qq.com

Treatment response and bile acid composition characteristics in late-onset intrahepatic cholestasis of pregnancy

Li Yuexin1, Qiu Ju1, Zhu Shasha2, Qian Jin1   

  1. 1. Department of Obstetrics and Gynecology, Rugao People's Hospital, Rugao 226500,China;
    2. Department of Laboratory Medicine, Rugao People's Hospital, Nantong 226500,China
  • Received:2026-01-18 Online:2026-09-30 Published:2026-11-16
  • Contact: Qian Jin, Email: 361741379@qq.com

摘要: 目的 探讨不同方案治疗晚发型妊娠期肝内胆汁淤积症(ICP)的疗效,并分析其胆汁酸组成特征。方法 收集 2021年3月至2024年12月如皋市人民医院确诊为晚发型ICP的患者94例。根据治疗方案不同分为标准治疗组和联合治疗组,比较两组疗效;根据疾病严重程度分为轻度ICP组和重度ICP组,分析不同严重程度患者的疗效及胆汁酸组成;并按治疗反应分为应答组与无应答组,比较不同疗效反应患者的胆汁酸谱特征。比较指标包括血清总胆汁酸(TBA)、肝功能指标、临床症状改善情况及胆汁酸组成比例。结果 治疗后,联合治疗组TBA水平低于标准治疗组,为(10.9±5.3)μmol/L比(15.8±6.7)μmol/L(P<0.05),TBA下降幅度更大,为(18.2±4.9)μmol/L比(12.6±3.0)μmol/L(P<0.05),瘙痒缓解率(81.8%比62.0%)及治疗应答率(77.3%比54.0%)均明显提高(P<0.05)。轻度ICP组TBA下降幅度高于重度ICP组,为(58.4±21.3)%比(37.4±17.2)%(P<0.05),治疗后TBA水平较低,为(11.6±5.8)μmol/L比(23.9±8.4)μmol/L(P<0.05),应答率更高(72.1%比46.2%,P<0.05)。胆汁酸组成方面,重度ICP组胆酸[(31.5±7.2)%比(24.1±6.3)%]、鹅去氧胆酸[(41.2±8.5)%比(33.7±7.8)%]、石胆酸[(6.8±2.7)%比(4.3±1.9)%]及结合胆汁酸比例[(72.4±11.2)%比(58.9±10.6)%]升高,而去氧胆酸比例降低[(15.4±4.8)%比(21.6±5.9)%](均P<0.05)。无应答组治疗前TBA水平高于应答组[(35.6±11.4)μmol/L比(23.7±8.9)μmol/L,P<0.05],且胆酸、鹅去氧胆酸、石胆酸比例升高,去氧胆酸比例降低(均P<0.05)。结论 晚发型ICP患者的疗效反应与治疗方案、疾病严重程度及胆汁酸组成特征密切相关。联合治疗可显著改善临床疗效,而胆汁酸谱改变可能影响治疗反应。胆汁酸组成特征有望成为评估晚发型ICP病情及预测疗效反应的潜在指标。

关键词: 妊娠期肝内胆汁淤积症, 总胆汁酸, 胆汁酸谱

Abstract: Objective To investigate the therapeutic response to different treatment regimens in patients with late-onset intrahepatic cholestasis of pregnancy (ICP) and to analyze the relationship between bile acid composition characteristics and treatment response. Methods A total of 94 pregnant women diagnosed with late-onset ICP from Rugao People's Hospital between March 2021 and December 2024 were enrolled. According to treatment regimens, patients were divided into a standard treatment group and a combination therapy group, and therapeutic outcomes were compared between the two groups. According to disease severity, patients were categorized into mild ICP and severe ICP groups, and differences in therapeutic efficacy and bile acid composition were analyzed. Patients were further classified into responders and non-responders based on treatment response, and bile acid profile characteristics were compared between these groups. Outcome measures included serum total bile acids (TBA), liver function parameters, improvement of clinical symptoms, and the proportions of bile acid components. Results After treatment, the TBA level in the combination therapy group was lower than that in the standard treatment group [(10.9±5.3) μmol/L vs. (15.8±6.7) μmol/L, P<0.05], with a greater reduction in TBA [(18.2±4.9) μmol/L vs. (12.6±3.0) μmol/L, P<0.05]. The pruritus relief rate (81.8% vs. 62.0%) and overall treatment response rate (77.3% vs. 54.0%) were both significantly higher (P<0.05). The mild ICP group showed a greater percentage reduction in TBA than the severe ICP group [(58.4±21.3)% vs. (37.4±17.2)%, P<0.05], lower post-treatment TBA levels [(11.6±5.8) μmol/L vs. (23.9±8.4) μmol/L, P<0.05], and a higher response rate (72.1% vs 46.2%, P<0.05). Regarding bile acid composition, the severe ICP group exhibited higher proportions of CA [(31.5±7.2)% vs. (24.1±6.3)%], CDCA [(41.2±8.5)% vs. (33.7±7.8)%], LCA [(6.8±2.7)% vs. (4.3±1.9)%], and proportion of conjugated bile acids [(72.4±11.2)% vs. (58.9±10.6)%], but a lower proportion of DCA [(15.4±4.8)% vs. (21.6±5.9)%] (all P<0.05). The non-responder group had higher baseline TBA levels than the responder group [(35.6±11.4) μmol/L vs. (23.7±8.9) μmol/L, P<0.05], with increased proportions of CA, CDCA, and LCA and a decreased proportion of DCA (all P<0.05). Conclusion Treatment response in patients with late-onset ICP is closely associated with treatment regimen, disease severity, and bile acid composition characteristics. Combination therapy can significantly improve clinical outcomes, while alterations in bile acid profiles may influence therapeutic response. Bile acid composition characteristics may serve as potential indicators for assessing disease status and predicting treatment response in late-onset ICP.

Key words: Intrahepatic cholestasis of pregnancy, Total bile acids, Bile acid profile